Login to Your Account

Transaction Valued at $8.5B

Not 'Growthy,' Tax-Wise Deal: Actavis Takes Warner Chilcott

By Randy Osborne
Staff Writer

Tuesday, May 21, 2013
Generic drugmaker Actavis Inc.'s plan to take over Dublin, Ireland-based Warner Chilcott plc in a stock-for-stock transaction worth about $8.5 billion, thus forming the world's third-largest specialty pharmaceutical firm, would put the combined firm – with about $11 billion in annual revenues – on even more solid footing in the busily consolidating biosimilars realm.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription